Publication date: Sep 06, 2019
A limited evidence base and lack of clear clinical guidelines challenge healthcare systems’ adoption of precision medicine. The effect of these conditions on demand is not understood.
This research estimated the public’s preferences and demand for precision medicine outcomes.
A discrete-choice experiment survey was conducted with an online sample of the US public who had recent healthcare experience. Statistical analysis was undertaken using an error components mixed logit model. The responsiveness of demand in the context of a changing evidence base was estimated through the price elasticity of demand. External validation was examined using real-world demand for the 21-gene recurrence score assay for breast cancer.
In total, 1124 (of 1849) individuals completed the web-based survey. The most important outcomes were survival gains with statistical uncertainty, cost of testing, and medical expert agreement on changing care based on test results. The value ($US, year 2017 values) for a test where most (vs. few) experts agreed to changing treatment based on test results was $US1100 (95% confidence interval [CI] 916-1286). Respondents were willing to pay $US265 (95% CI 46-486) for a test that could result in greater certainty around life-expectancy gains. The predicted demand of the assay was 9% in 2005 and 66% in 2014, compared with real-world uptake of 7% and 71% (root-mean-square prediction error 0.11). Demand was sensitive to price (1% increase in price resulted in > 1% change in demand) when first introduced and insensitive to price (1% increase in price resulted in
Regier, D.A., Veenstra, D.L., Basu, A., and Carlson, J.J. Demand for Precision Medicine: A Discrete-Choice Experiment and External Validation Study. 05345. 2019 Pharmacoeconomics.
- Adaptive Signature Design- review of the biomarker guided adaptive phase -III controlled design.
- Personalized Medicine Implementation with Non-traditional Data Sources: A Conceptual Framework and Survey of the Literature.
- Genomic Prediction of Complex Traits and Disease Risks via AI/ML and Large Genomic Datasets
- Precision medicine: Advanced data analysis enhances prenatal genetic testing
- Diversity of ATM gene variants: a population-based genome data analysis for precision medicine.